Envoy Medical (COCH) Expected to Release Quarterly Earnings on Thursday

Envoy Medical (NASDAQ:COCH) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.70) per share and revenue of $0.09 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 9:30 AM ET.

Envoy Medical (NASDAQ:COCH) last announced its earnings results on Monday, August 10th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.10. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.05 million. On average, analysts expect Envoy Medical to post ($3.10) EPS for the current fiscal year and ($1.80) EPS for the next fiscal year.

Envoy Medical Stock Down 0.5%

Envoy Medical stock opened at $6.62 on Wednesday. The stock has a market capitalization of $51.11 million, a PE ratio of -0.87 and a beta of 2.03. Envoy Medical has a twelve month low of $3.63 and a twelve month high of $9.54. The company has a 50 day moving average of $6.83 and a 200-day moving average of $6.87.

Analyst Upgrades and Downgrades

COCH has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Loop Capital set a $20.00 target price on shares of Envoy Medical in a research note on Monday, July 27th. HC Wainwright reiterated a “buy” rating on shares of Envoy Medical in a report on Tuesday, October 13th. Finally, Lake Street Capital lifted their price target on Envoy Medical from $2.50 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $21.67.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.